Krishnansu S Tewari1, James J Java2, Troy A Gatcliffe3, Michael A Bookman4, Bradley J Monk5. 1. Dept. of Obstetrics & Gynecology, University of California, Irvine Medical Center, Orange, CA 92868, USA. Electronic address: ktewari@uci.edu. 2. Gynecologic Oncology Group Statistical & Data Center, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. 3. Dept. of Obstetrics & Gynecology, GYN Oncology of Miami, Miami, FL 33176, USA. 4. Division of Hematology-Oncology, University of Arizona Cancer Center, Tucson, AZ 85724, USA. 5. Dept. of Obstetrics & Gynecology, Division of Gynecologic Oncology, University of Arizona Cancer Center, Creighton University School of Medicine, St. Joseph's Hospital & Medical Center, Phoenix, AZ 85013, USA.
Abstract
OBJECTIVE: To determine whether chemotherapy-induced neutropenia (C-iN) is associated with improved survival in a population of primary advanced ovarian cancer and peritoneal carcinoma patients treated with a carboplatin plus paclitaxel chemotherapy backbone. METHODS: A post-hoc exploratory analysis of Gynecologic Oncology Group (GOG) protocol 182 was performed. Landmark analysis was conducted on all patients with progression-free survival >18weeks from the time of study entry. Neutropenia was defined as the absolute neutrophil count <1000mm(3). The occurrence of C-iN was analyzed according to demographic, clinicopathologic, and therapeutic intent, including age, body surface area, and treatment arm. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. The Cox proportional hazards model was used to evaluate independent prognostic factors and to estimate their effects on PFS and OS. RESULTS: Neutropenic data was available for 3447 patients. Neutropenic (n=3196) and non-neutropenic groups (n=251) were similar in demographic and clinicopathologic characteristics. Neutropenic patients experienced significantly improved survival compared to non-neutropenic patients with the adjusted hazard ratio (HR) for death being 0.86 (95% confidence interval 0.74-0.99; p=0.041). There was no survival benefit associated with any of the treatment arms among patients with C-iN. CONCLUSION: These data suggest that C-iN may represent a clinical biomarker associated with a survival advantage for patients with untreated advanced ovarian cancer. The absence of C-iN may indicate under-dosing and ultimately attenuated anti-neoplastic effect in vulnerable populations.
OBJECTIVE: To determine whether chemotherapy-induced neutropenia (C-iN) is associated with improved survival in a population of primary advanced ovarian cancer and peritoneal carcinomapatients treated with a carboplatin plus paclitaxel chemotherapy backbone. METHODS: A post-hoc exploratory analysis of Gynecologic Oncology Group (GOG) protocol 182 was performed. Landmark analysis was conducted on all patients with progression-free survival >18weeks from the time of study entry. Neutropenia was defined as the absolute neutrophil count <1000mm(3). The occurrence of C-iN was analyzed according to demographic, clinicopathologic, and therapeutic intent, including age, body surface area, and treatment arm. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. The Cox proportional hazards model was used to evaluate independent prognostic factors and to estimate their effects on PFS and OS. RESULTS:Neutropenic data was available for 3447 patients. Neutropenic (n=3196) and non-neutropenic groups (n=251) were similar in demographic and clinicopathologic characteristics. Neutropenicpatients experienced significantly improved survival compared to non-neutropenicpatients with the adjusted hazard ratio (HR) for death being 0.86 (95% confidence interval 0.74-0.99; p=0.041). There was no survival benefit associated with any of the treatment arms among patients with C-iN. CONCLUSION: These data suggest that C-iN may represent a clinical biomarker associated with a survival advantage for patients with untreated advanced ovarian cancer. The absence of C-iN may indicate under-dosing and ultimately attenuated anti-neoplastic effect in vulnerable populations.
Authors: Belinda Yeo; Andrew D Redfern; Kellie A Mouchemore; John A Hamilton; Robin L Anderson Journal: Clin Exp Metastasis Date: 2018-07-02 Impact factor: 5.150
Authors: Raimundo Fernandes de Araújo; Maria Patrícia Oliveira da Silva Reinaldo; Gerly Anne de Castro Brito; Pedro de França Cavalcanti; Marco Aurélio Freire; Marco Aurélio de Moura Freire; Caroline Addison Xavier de Medeiros; Aurigena Antunes de Araújo Journal: PLoS One Date: 2014-12-22 Impact factor: 3.240
Authors: Pashtoon M Kasi; Daisuke Kotani; Michael Cecchini; Kohei Shitara; Atsushi Ohtsu; Ramesh K Ramanathan; Howard S Hochster; Axel Grothey; Takayuki Yoshino Journal: BMC Cancer Date: 2016-07-13 Impact factor: 4.430